Cyclopharm (ASX:CYC) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

CYC Overzicht aandelen

Cyclopharm Limited produceert en verkoopt medische apparatuur en radiofarmaceutica in Azië, Europa, Canada en internationaal.

Over het bedrijf

CYC fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 85.6% onder onze schatting van de reële waarde

De winst zal naar verwachting met 104.88% per jaar groeien

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar verwaterd

Cyclopharm Limited Concurrenten

Optiscan Imaging

ASX:OIL

AU$137.8m

ImpediMed

ASX:IPD

AU$117.3m

Austco Healthcare

ASX:AHC

AU$96.5m

SomnoMed

ASX:SOM

AU$84.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Cyclopharm
Historische aandelenkoersen
Huidige aandelenkoers	AU$1.75
52 Week Hoogtepunt	AU$2.55
52 Week Laag	AU$1.35
Bèta	0.70
11 maand verandering	16.67%
3 maanden verandering	4.17%
1 Jaar Verandering	-30.00%
33 jaar verandering	6.06%
5 jaar verandering	37.80%
Verandering sinds IPO	-6.67%

Recent nieuws en updates

Recent updates

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Oct 28

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Mar 02

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

Oct 22

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Jun 29

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Apr 27

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Mar 01

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

Feb 07

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

Jan 02

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

Dec 06

Rendement voor aandeelhouders

	CYC	AU Medical Equipment	AU Markt
7D	19.0%	2.1%	-0.7%
1Y	-30.0%	16.0%	17.1%

Rendement versus industrie: CYC presteerde slechter dan de Australian Medical Equipment -sector, die het afgelopen jaar een rendement van 16.5 % opleverde.

Rendement versus markt: CYC presteerde slechter dan Australian Market, dat het afgelopen jaar een rendement van 17.9 % opleverde.

Prijsvolatiliteit

Is CYC's price volatile compared to industry and market?
CYC volatility
CYC Average Weekly Movement	5.8%
Medical Equipment Industry Average Movement	9.8%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.7%

Stabiele aandelenkoers: CYC heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van CYC is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1986	87	James McBrayer	www.cyclopharm.com

Cyclopharm Limited produceert en verkoopt medische apparatuur en radiofarmaceutica in Azië, Europa, Canada en internationaal. Het bedrijf opereert via de segmenten Technegas en Molecular Imaging. Het Technegas-segment biedt diagnostische apparatuur en verbruiksartikelen die door artsen worden gebruikt bij het opsporen van longembolie.

Cyclopharm Limited Samenvatting

Hoe verhouden de winst en inkomsten van Cyclopharm zich tot de beurswaarde?
CYC fundamentele statistieken
Marktkapitalisatie	AU$194.49m
Inkomsten(TTM)	-AU$9.32m
Inkomsten(TTM)	AU$24.06m

8.1x

P/S-verhouding

-20.9x

Koers/Winstverhouding

Is CYC overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CYC resultatenrekening (TTM)
Inkomsten	AU$24.06m
Kosten van inkomsten	AU$10.23m
Brutowinst	AU$13.82m
Overige uitgaven	AU$23.14m
Inkomsten	-AU$9.32m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.084
Brutomarge	57.47%
Nettowinstmarge	-38.72%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde CYC op de lange termijn?

Bekijk historische prestaties en vergelijking

CYC Overzicht aandelen

Beloningen

Risicoanalyse

Cyclopharm Limited Concurrenten

ASX:OIL

AU$137.8m

ASX:IPD

AU$117.3m

ASX:AHC

AU$96.5m

ASX:SOM

AU$84.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Non-Executive Director recently bought AU$51k worth of stock

Consensus revenue estimates fall by 13%

First half 2024 earnings released: AU$0.078 loss per share (vs AU$0.032 loss in 1H 2023)

Forecast breakeven date pushed back to 2026

New minor risk - Shareholder dilution

Cyclopharm Limited has completed a Follow-on Equity Offering in the amount of AUD 20.000001 million.

Recent updates

Non-Executive Director recently bought AU$51k worth of stock

Consensus revenue estimates fall by 13%

First half 2024 earnings released: AU$0.078 loss per share (vs AU$0.032 loss in 1H 2023)

Forecast breakeven date pushed back to 2026

New minor risk - Shareholder dilution

Cyclopharm Limited has completed a Follow-on Equity Offering in the amount of AUD 20.000001 million.

Cyclopharm Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New minor risk - Market cap size

Consensus revenue estimates fall by 14%

Cyclopharm Limited, Annual General Meeting, May 27, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director

Consensus EPS estimates fall by 11%

CEO, MD exercised options to buy AU$402k worth of stock.

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Forecast breakeven date pushed back to 2025

First half 2023 earnings released: AU$0.032 loss per share (vs AU$0.028 loss in 1H 2022)

Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023

Consensus estimates of losses per share improve by 13%

Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?

Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth

Consensus EPS estimates fall by 153%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023

Less than half of directors are independent

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Less than half of directors are independent

Cyclopharm Limited Appoints Gregory King as A Non-Executive Director

Cyclopharm Limited Appoints Kevin Barrow as A Nonexecutive Director

First half 2022 earnings released: AU$0.028 loss per share (vs AU$0.045 loss in 1H 2021)

Cyclopharm Limited Declares an Unfranked Dividend for the Half Year Ended June 30, 2022, Payable on 12 September 2022

Consensus revenue estimates increase by 10%

Cyclopharm Limited Announces Independent Multicentre Study Highlights the Benefits of Technegas in Diagnosing Pulmonary Embolism in Growing Covid-19 Patient Population

Cyclopharm Limited Provides Sales Guidance for the Half Year Ended 30 June 2022

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Cyclopharm Limited Announces Technegas Used in Diagnosing Long COVID

Full year 2021 earnings: Revenues exceed analyst expectations

Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Consensus revenue estimates increase by 14%

Forecast to breakeven in 2024

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for Period of Six Months Ended December 31, 2021, Payable on April 12, 2022

Cyclopharm Limited Provides Earnings Guidance for the Full Year 2021

Less than half of directors are independent

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

First half 2021 earnings released: AU$0.045 loss per share (vs AU$0.074 loss in 1H 2020)

Cyclopharm Limited Provides Unaudited Revenue Guidance for the First Half of 2021

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Consensus revenue estimates fall to AU$16.5m

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Cyclopharm Limited provides Confirmation of Technegas USFDA Timetable

Analysts increase revenue estimates to AU$18.6m

Cyclopharm Limited, Annual General Meeting, May 04, 2021

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Cyclopharm Limited Provides Update on USFDA Approval to Distribute Technegas in the USA in 2021